Zaky, M.F.; Hammady, T.M.; Gad, S.; Alattar, A.; Alshaman, R.; Hegazy, A.; Zaitone, S.A.; Ghorab, M.M.; Megahed, M.A.
Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban. Pharmaceutics 2023, 15, 1668.
https://doi.org/10.3390/pharmaceutics15061668
AMA Style
Zaky MF, Hammady TM, Gad S, Alattar A, Alshaman R, Hegazy A, Zaitone SA, Ghorab MM, Megahed MA.
Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban. Pharmaceutics. 2023; 15(6):1668.
https://doi.org/10.3390/pharmaceutics15061668
Chicago/Turabian Style
Zaky, Mohamed F., Taha M. Hammady, Shadeed Gad, Abdullah Alattar, Reem Alshaman, Ann Hegazy, Sawsan A. Zaitone, Mamdouh Mostafa Ghorab, and Mohamed A. Megahed.
2023. "Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban" Pharmaceutics 15, no. 6: 1668.
https://doi.org/10.3390/pharmaceutics15061668
APA Style
Zaky, M. F., Hammady, T. M., Gad, S., Alattar, A., Alshaman, R., Hegazy, A., Zaitone, S. A., Ghorab, M. M., & Megahed, M. A.
(2023). Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban. Pharmaceutics, 15(6), 1668.
https://doi.org/10.3390/pharmaceutics15061668
